Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study.
about
IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis.Brodalumab for the treatment of psoriasis.Interleukin-17 blockade in generalized pustular psoriasis - new hope for severely ill patients.Phenotypical analysis of ectoenzymes CD39/CD73 and adenosine receptor 2A in CD4+ CD25high Foxp3+ regulatory T-cells in psoriasis.Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.
P2860
Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Efficacy and safety of brodalu ...... m a 52-week, open-label study.
@en
Efficacy and safety of brodalu ...... m a 52-week, open-label study.
@nl
type
label
Efficacy and safety of brodalu ...... m a 52-week, open-label study.
@en
Efficacy and safety of brodalu ...... m a 52-week, open-label study.
@nl
prefLabel
Efficacy and safety of brodalu ...... m a 52-week, open-label study.
@en
Efficacy and safety of brodalu ...... m a 52-week, open-label study.
@nl
P2093
P2860
P356
P1476
Efficacy and safety of brodalu ...... m a 52-week, open-label study.
@en
P2093
H Nakagawa
Japanese Brodalumab Study Group
P2860
P304
P356
10.1111/BJD.14702
P407
P50
P577
2016-10-02T00:00:00Z